Condition: Colon Cancer · Sponsor: Seoul National University Hospital
This study is a prospective, open-label, randomized phase 3 clinical trial. It aims to investigate if the early introduction of intensified chemotherapy (3 months of modified FOLFIRINOX) improves the 3-year disease-free survival rate compared to standard treatment (FOLFOX/CAPOX for an additional three months to complete six months of standard adjuvant chemotherapy) in patients with stage 2-3 colon cancer in whom ctDNA MRD in the part 1 study remained positive during adjuvant FOLFOX/CAPOX chemotherapy
This description comes directly from the study's public registry record.
Sae-Won Han, MD,PhD · 82-2-2072-0795 · saewon1@snu.ac.kr
Youngjun Cha, MD · 82-2-2072-0795 · yongjuncha@ncc.re.kr
Always discuss trial participation with your own doctor first.
| National Cancer Center | Goyang, South Korea | Recruiting |
| Jin Won Kim | Seongnam, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05534087